Journal article

Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study

Abstract:: Background: We sought to report the effectiveness of infliximab and adalimumab over the first 3 years of treatment and to define the factors that predict anti-TNF treatment failure and the strategies that prevent or mitigate loss of response.

Methods: Personalised Anti-TNF therapy in Crohn's disease (PANTS) is a UK-wide, multicentre, prospective observational cohort study reporting the rates of effectiveness of infliximab and adalimumab in an...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Chanchlani, N., Lin, S., Bewshea, C., Hamilton, B., Thomas, A., Smith, R., Roberts, C., Bishara, M., Nice, R., Lees, C. W., Sebastian, S., Irving, P. M., Russell, R. K., McDonald, T. J., Goodhand, J. R., Ahmad, T., & Kennedy, N. A. (2024). Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study. Lancet Gastroenterology and Hepatology, 9(6), 521–538.

MLA Style

Chanchlani, N, et al. “Mechanisms and Management of Loss of Response to Anti-TNF Therapy for Patients with Crohn's Disease: 3-Year Data from the Prospective, Multicentre PANTS Cohort Study.” Lancet Gastroenterology and Hepatology, vol. 9, no. 6, 2024, pp. 521–38.

Chicago Style

Chanchlani, N, S Lin, C Bewshea, et al. 2024. “Mechanisms and Management of Loss of Response to Anti-TNF Therapy for Patients with Crohn's Disease: 3-Year Data from the Prospective, Multicentre PANTS Cohort Study.” Lancet Gastroenterology and Hepatology 9 (6): 521–38.
Print

Access Document

Files:: Chanchlani_et_al_2024_Mechanisms_and_management.pdf

(Preview, Version of record, pdf, 901.8KB, Terms of use)

Publisher copy:: 10.1016/s2468-1253(24)00044-x

Authors

+ Chanchlani, N More by this author

Role:: Author

+ Lin, S More by this author

Role:: Author

+ Bewshea, C More by this author

Role:: Author

+ Hamilton, B More by this author

Role:: Author

+ Thomas, A More by this author

Role:: Author

More authors...

Contributors

+ PANTS Consortium

Role:: Contributor

Institution:: University of Oxford
Division:: MSD
Department:: RDM
Role:: Contributor

+ Crohn's & Colitis UK More from this funder

Publisher:: Elsevier
Journal:: Lancet Gastroenterology and Hepatology More from this journal
Volume:: 9
Issue:: 6
Pages:: 521-538
Publication date:: 2024-04-16
DOI:: 10.1016/s2468-1253(24)00044-x
EISSN:: 2468-1253
Pmid:: 38640937

Language:: English
Keywords:: Tumor Necrosis Factor-alpha

prospective studies

Infliximab

treatment failure

United Kingdom

adalimumab

Crohn Disease

remission induction

PANTS Consortium
Pubs id:: 1997974
Local pid:: pubs:1997974
Deposit date:: 2024-05-24
ARK identifier:: ark:/29072/ora_7da12db13df349a28ff059c4d07b635b

Terms of use

Copyright holder:: Chanchlani et al.
Copyright date:: 2024
Rights statement:: © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP